Abstract
Blueberries are amongst the most commonly consumed berries in the United States. Berries in general are rich in phenolic compounds, which are known for their high antioxidant capacity. Specifically, evidence from in vitro, in vivo and a few clinical studies suggest that blueberries and their active constituents show promise as effective anti-cancer agents, both in the form of functional foods and as nutritional supplements. Some of the mechanisms by which blueberries have been shown to prevent carcinogenesis include inhibition of the production of pro-inflammatory molecules, oxidative stress and products of oxidative stress such as DNA damage, inhibition of cancer cell proliferation and increased apoptosis. This review will focus on the preclinical and clinical evidence that supports blueberries as an anti-cancer fruit, as well as expressing the need for more preclinical studies and the conduction of clinical studies with respect to the cancer preventive ability of blueberries.
Keywords: Antioxidant, cancer prevention, carcinogenesis, chemoprevention, DNA damage, functional food, inflammation, oxidative stress, polyphenol, pterostilbene, tumorigenesis, vaccinium
Anti-Cancer Agents in Medicinal Chemistry
Title:Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review
Volume: 13 Issue: 8
Author(s): Sarah A. Johnson and Bahram H. Arjmandi
Affiliation:
Keywords: Antioxidant, cancer prevention, carcinogenesis, chemoprevention, DNA damage, functional food, inflammation, oxidative stress, polyphenol, pterostilbene, tumorigenesis, vaccinium
Abstract: Blueberries are amongst the most commonly consumed berries in the United States. Berries in general are rich in phenolic compounds, which are known for their high antioxidant capacity. Specifically, evidence from in vitro, in vivo and a few clinical studies suggest that blueberries and their active constituents show promise as effective anti-cancer agents, both in the form of functional foods and as nutritional supplements. Some of the mechanisms by which blueberries have been shown to prevent carcinogenesis include inhibition of the production of pro-inflammatory molecules, oxidative stress and products of oxidative stress such as DNA damage, inhibition of cancer cell proliferation and increased apoptosis. This review will focus on the preclinical and clinical evidence that supports blueberries as an anti-cancer fruit, as well as expressing the need for more preclinical studies and the conduction of clinical studies with respect to the cancer preventive ability of blueberries.
Export Options
About this article
Cite this article as:
Johnson A. Sarah and Arjmandi H. Bahram, Evidence for Anti-Cancer Properties of Blueberries: A Mini-Review, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (8) . https://dx.doi.org/10.2174/18715206113139990137
DOI https://dx.doi.org/10.2174/18715206113139990137 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy
Current Medicinal Chemistry The Extracapsular Lymph Node Extension Predicts Outcomes in Colorectal Cancer: A Short Review
Current Drug Targets Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets Editorial (Hot Topic: miRNA in the Pathogenesis and Therapy for Gastrointestinal and Hepatic Cancers)
Current Pharmaceutical Design Multidisciplinary Cancer Therapy with Telomerase-Specific Oncolytic Adenovirus
Current Cancer Therapy Reviews Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy MicroRNAs as Cancer Biomarkers
MicroRNA The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews